Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2016, Article ID 9150108, 14 pages
http://dx.doi.org/10.1155/2016/9150108
Review Article

Molecular Mechanisms of Cardioprotective Actions of Tanshinones

1National Institute of Complementary Medicine, Western Sydney University, Penrith, NSW 2751, Australia
2Division of Chinese Medicine, School of Health Sciences, RMIT University, Bundoora, VIC 3083, Australia

Received 22 October 2015; Accepted 17 January 2016

Academic Editor: Hani El-Nezami

Copyright © 2016 Hyou-Ju Jin and Chun-Guang Li. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Zhou, Z. Zuo, and M. S. S. Chow, “Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use,” Journal of Clinical Pharmacology, vol. 45, no. 12, pp. 1345–1359, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Wu, M. Liu, and S. Zhang, “Dan Shen agents for acute ischemic stroke,” Stroke, vol. 38, no. 11, pp. 3095–3096, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. T. O. Cheng, “Danshen: a versatile Chinese herbal drug for the treatment of coronary heart disease,” International Journal of Cardiology, vol. 113, no. 3, pp. 437–438, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. J. D. Adams, R. Wang, J. Yang, and E. J. Lien, “Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions,” Chinese Medicine, vol. 1, article 3, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Jia, F. Huang, S. Zhang, and S.-W. Leung, “Is danshen (Salvia miltiorrhiza) dripping pill more effective than isosorbide dinitrate in treating angina pectoris? A systematic review of randomized controlled trials,” International Journal of Cardiology, vol. 157, no. 3, pp. 330–340, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Dong, S. L. Morris-Natschke, and K.-H. Lee, “Biosynthesis, total syntheses, and antitumor activity of tanshinones and their analogs as potential therapeutic agents,” Natural Product Reports, vol. 28, no. 3, pp. 529–542, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Chen, X. Wu, S. Yu et al., “Neuroprotective capabilities of tanshinone IIA against cerebral ischemia/reperfusion injury via anti-apoptotic pathway in rats,” Biological and Pharmaceutical Bulletin, vol. 35, no. 2, pp. 164–170, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Wang, W. Zhang, T. Wang et al., “Unveiling the mode of action of two antibacterial tanshinone derivatives,” International Journal of Molecular Sciences, vol. 16, no. 8, pp. 17668–17681, 2015. View at Publisher · View at Google Scholar
  9. X. Wang, S. L. Morris-Natschke, and K.-H. Lee, “New developments in the chemistry and biology of the bioactive constituents of tanshen,” Medicinal Research Reviews, vol. 27, no. 1, pp. 133–148, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J.-Y. Han, J.-Y. Fan, Y. Horie et al., “Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion,” Pharmacology and Therapeutics, vol. 117, no. 2, pp. 280–295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J.-Y. Han, Y. Horie, S. Miura et al., “Compound Danshen injection improves endotoxin-induced microcirculatory disturbance in rat mesentery,” World Journal of Gastroenterology, vol. 13, no. 26, pp. 3581–3591, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Zhang, P. Jiang, M. Ye, S.-H. Kim, C. Jiang, and J. Lü, “Tanshinones: sources, pharmacokinetics and anti-cancer activities,” International Journal of Molecular Sciences, vol. 13, no. 10, pp. 13621–13666, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Xu and P. Liu, “Tanshinone II-A: new perspectives for old remedies,” Expert Opinion on Therapeutic Patents, vol. 23, no. 2, pp. 149–153, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. Q. Liu, Y. Zhang, Z. Lin et al., “Danshen extract 15,16-dihydrotanshinone I functions as a potential modulator against metabolic syndrome through multi-target pathways,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 120, no. 4-5, pp. 155–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Q. Shang, H. Xu, and L. Huang, “Tanshinone IIA: a promising natural cardioprotective agent,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 716459, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. G.-B. Wu, E.-X. Zhou, and D.-X. Qing, “Tanshinone IIA elicited vasodilation in rat coronary arteriole: roles of nitric oxide and potassium channels,” European Journal of Pharmacology, vol. 617, no. 1–3, pp. 102–107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. K.-J. Huang, H. Wang, W.-Z. Xie, and H.-S. Zhang, “Investigation of the effect of tanshinone IIA on nitric oxide production in human vascular endothelial cells by fluorescence imaging,” Spectrochimica Acta—Part A: Molecular and Biomolecular Spectroscopy, vol. 68, no. 5, pp. 1180–1186, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. Z. H. Ren, Y. H. Tong, W. Xu, J. Ma, and Y. Chen, “Tanshinone II A attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression,” Phytomedicine, vol. 17, no. 3-4, pp. 212–218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Fu, H. Huang, J. Liu, R. Pi, J. Chen, and P. Liu, “Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis,” European Journal of Pharmacology, vol. 568, no. 1–3, pp. 213–221, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Yuan, S. Jing, L. Wu, L. Chen, and J. Fang, “Pharmacological postconditioning with tanshinone IIA attenuates myocardial ischemia-reperfusion injury in rats by activating the phosphatidylinositol 3-kinase pathway,” Experimental and Therapeutic Medicine, vol. 8, no. 3, pp. 973–977, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. H.-J. Hong, J.-C. Liu, P.-Y. Chen, J.-J. Chen, P. Chan, and T.-H. Cheng, “Tanshinone IIA prevents doxorubicin-induced cardiomyocyte apoptosis through Akt-dependent pathway,” International Journal of Cardiology, vol. 157, no. 2, pp. 174–179, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. F.-T. Tang, Y. Cao, T.-Q. Wang et al., “Tanshinone IIA attenuates atherosclerosis in ApoE−/− mice through down-regulation of scavenger receptor expression,” European Journal of Pharmacology, vol. 650, no. 1, pp. 275–284, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. S.-J. Suh, U.-H. Jin, H.-J. Choi et al., “Cryptotanshinone from Salvia miltiorrhiza BUNGE has an inhibitory effect on TNF-α-induced matrix metalloproteinase-9 production and HASMC migration via down-regulated NF-κB and AP-1,” Biochemical Pharmacology, vol. 72, no. 12, pp. 1680–1689, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. C. Jin, C. W. Kim, Y. M. Kim et al., “Cryptotanshinone, a lipophilic compound of Salvia miltiorrriza root, inhibits TNF-α-induced expression of adhesion molecules in HUVEC and attenuates rat myocardial ischemia/reperfusion injury in vivo,” European Journal of Pharmacology, vol. 614, no. 1–3, pp. 91–97, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. F. F. Y. Lam, J. H. K. Yeung, K. M. Chan, and P. M. Y. Or, “Mechanisms of the dilator action of cryptotanshinone on rat coronary artery,” European Journal of Pharmacology, vol. 578, no. 2-3, pp. 253–260, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. Z. Zhou, S.-Q. Wang, Y. Liu, and A.-D. Miao, “Cryptotanshinone inhibits endothelin-1 expression and stimulates nitric oxide production in human vascular endothelial cells,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1760, no. 1, pp. 1–9, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Maki, Y. Kawahara, K. Tanonaka, A. Yagi, and S. Takeo, “Effects of tanshinone VI on the hypertrophy of cardiac myocytes and fibrosis of cardiac fibroblasts of neonatal rats,” Planta Medica, vol. 68, no. 12, pp. 1103–1107, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. F. F. Y. Lam, J. H. K. Yeung, K. M. Chan, and P. M. Y. Or, “Dihydrotanshinone, a lipophilic component of Salvia miltiorrhiza (danshen), relaxes rat coronary artery by inhibition of calcium channels,” Journal of Ethnopharmacology, vol. 119, no. 2, pp. 318–321, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J.-W. Park, S.-H. Lee, M.-K. Yang et al., “15,16-Dihydrotanshinone I, a major component from Salvia miltiorrhiza Bunge (Dansham), inhibits rabbit platelet aggregation by suppressing intracellular calcium mobilization,” Archives of Pharmacal Research, vol. 31, no. 1, pp. 47–53, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Schäfer, M. Rodríguez, and G. Siegel, “Atherosclerosis, an inflammatory and fibroproliferative disease. A prophylactic phytochemical approach with Ginkgo biloba (EGb 761),” Atherosclerosis, vol. 195, no. 2, pp. 419–422, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Hirase and K. Node, “Endothelial dysfunction as a cellular mechanism for vascular failure,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 302, no. 3, pp. H499–H505, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. H. K. Saini, Y.-J. Xu, A. S. Arneja, P. S. Tappia, and N. S. Dhalla, “Pharmacological basis of different targets for the treatment of atherosclerosis,” Journal of Cellular and Molecular Medicine, vol. 9, no. 4, pp. 818–839, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Wang, X. Gao, and B. Zhang, “Tanshinone: an inhibitor of proliferation of vascular smooth muscle cells,” Journal of Ethnopharmacology, vol. 99, no. 1, pp. 93–98, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. J.-R. Du, X. Li, R. Zhang, and Z.-M. Qian, “Tanshinone inhibits intimal hyperplasia in the ligated carotid artery in mice,” Journal of Ethnopharmacology, vol. 98, no. 3, pp. 319–322, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. H.-J. Jin and C.-G. Li, “Tanshinone IIA and cryptotanshinone prevent mitochondrial dysfunction in hypoxia-induced H9c2 cells: association to mitochondrial ROS, intracellular nitric oxide, and calcium levels,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 610694, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. H.-J. Jin, X.-L. Xie, J.-M. Ye, and C.-G. Li, “TanshinoneIIA and cryptotanshinone protect against hypoxia-induced mitochondrial apoptosis in H9c2 cells,” PLoS ONE, vol. 8, no. 1, Article ID e51720, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. I. T. Nizamutdinova, Y. M. Kim, H. Jin et al., “Tanshinone IIA inhibits TNF-α-mediated induction of VCAM-1 but not ICAM-1 through the regulation of GATA-6 and IRF-1,” International Immunopharmacology, vol. 14, no. 4, pp. 650–657, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Lin, W.-R. Wang, J.-T. Liu, G.-D. Yang, and C.-J. Han, “Protective effect of tanshinone IIA on human umbilical vein endothelial cell injured by hydrogen peroxide and its mechanism,” Journal of Ethnopharmacology, vol. 108, no. 2, pp. 217–222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Chan, Y.-C. Chen, L.-J. Lin et al., “Tanshinone IIA attenuates H2O2-induced injury in human umbilical vein endothelial cells,” The American Journal of Chinese Medicine, vol. 40, no. 6, pp. 1307–1319, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Pan, L. Lou, Y. Huo et al., “Salvianolic acid B and Tanshinone IIA attenuate myocardial ischemia injury in mice by no production through multiple pathways,” Therapeutic Advances in Cardiovascular Disease, vol. 5, no. 2, pp. 99–111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. H.-S. Zhang and S.-Q. Wang, “Nrf2 is involved in the effect of tanshinone IIA on intracellular redox status in human aortic smooth muscle cells,” Biochemical Pharmacology, vol. 73, no. 9, pp. 1358–1366, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. X. Li, J.-R. Du, Y. Yu, B. Bai, and X.-Y. Zheng, “Tanshinone IIA inhibits smooth muscle proliferation and intimal hyperplasia in the rat carotid balloon-injured model through inhibition of MAPK signaling pathway,” Journal of Ethnopharmacology, vol. 129, no. 2, pp. 273–279, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Gao, G. Yang, R. Pi et al., “Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis,” Translational Research, vol. 151, no. 2, pp. 79–87, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Yang, Y.-H. Jia, J. Li, L.-J. Li, and F.-H. Zhou, “Study of anti-myocardial cell oxidative stress action and effect of tanshinone IIA on prohibitin expression,” Journal of Traditional Chinese Medicine, vol. 30, no. 4, pp. 259–264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Zhang, Y. Wu, Y. Li et al., “Tanshinone IIA improves miR-133 expression through MAPK ERK1/2 pathway in hypoxic cardiac myocytes,” Cellular Physiology and Biochemistry, vol. 30, no. 4, pp. 843–852, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Zhang, L. Zhang, W. Chu et al., “Tanshinone IIA inhibits miR-1 expression through p38 MAPK signal pathway in post-infarction rat cardiomyocytes,” Cellular Physiology and Biochemistry, vol. 26, no. 6, pp. 991–998, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. X. Tan, J. Li, X. Wang et al., “Tanshinone IIA protects against cardiac hypertrophy via inhibiting cal-cineurin/Nfatc3 pathway,” International Journal of Biological Sciences, vol. 7, no. 3, pp. 383–389, 2011. View at Google Scholar · View at Scopus
  48. D.-X. Zhou, Q.-S. Liang, X.-X. He, and C.-Y. Zhan, “Changes of c-fos, c-jun mRNA expressions in cardiomyocyte hypertrophy induced by angiotensin II and effects of tanshinone II A,” Zhongguo Zhong Yao Za Zhi, vol. 33, no. 8, pp. 936–939, 2008. View at Google Scholar · View at Scopus
  49. H.-J. Hong, J.-C. Liu, T.-H. Cheng, and P. Chan, “Tanshinone IIA attenuates angiotensin II-induced apoptosis via Akt pathway in neonatal rat cardiomyocytes,” Acta Pharmacologica Sinica, vol. 31, no. 12, pp. 1569–1575, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Zhou, Z. Li, L. Zhang, and C. Zhan, “Inhibitory effect of tanshinone II A on TGF II-β1-induced cardiac fibrosis,” Journal of Huazhong University of Science and Technology [Medical Sciences], vol. 32, no. 6, pp. 829–833, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Chan, J.-C. Liu, L.-J. Lin et al., “Tanshinone IIA inhibits angiotensin II-induced cell proliferation in rat cardiac fibroblasts,” The American Journal of Chinese Medicine, vol. 39, no. 2, pp. 381–394, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. L. Yang, X.-J. Zou, X. Gao et al., “Sodium tanshinone IIA sulfonate attenuates angiotensin II-induced collagen type I expression in cardiac fibroblasts in vitro,” Experimental and Molecular Medicine, vol. 41, no. 7, pp. 508–516, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Wang, S. Zhou, L. Xu et al., “Hydrogen peroxide-mediated oxidative stress and collagen synthesis in cardiac fibroblasts: blockade by tanshinone IIA,” Journal of Ethnopharmacology, vol. 145, no. 1, pp. 152–161, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Mao, W. Li, N. Qa'aty, M. Vincent, M. Zhang, and A. Hinek, “Tanshinone IIA inhibits angiotensin II induced extracellular matrix remodeling in human cardiac fibroblasts—implications for treatment of pathologic cardiac remodeling,” International Journal of Cardiology, vol. 202, pp. 110–117, 2016. View at Publisher · View at Google Scholar
  55. W.-Y. Wu, W.-Y. Wang, Y.-L. Ma et al., “Sodium tanshinone IIA silate inhibits oxygen-glucose deprivation/recovery-induced cardiomyocyte apoptosis via suppression of the NF-κB/TNF-α pathway,” British Journal of Pharmacology, vol. 169, no. 5, pp. 1058–1071, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. T. Arino, K. Tanonaka, Y. Kawahara et al., “Effects of tanshinone VI on phosphorylation of ERK and Akt in isolated cardiomyocytes and cardiac fibroblasts,” European Journal of Pharmacology, vol. 580, no. 3, pp. 298–305, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. X. Wang, Y. Wang, M. Jiang et al., “Differential cardioprotective effects of salvianolic acid and tanshinone on acute myocardial infarction are mediated by unique signaling pathways,” Journal of Ethnopharmacology, vol. 135, no. 3, pp. 662–671, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. B. Wei, W.-W. Li, J. Ji, Q.-H. Hu, and H. Ji, “The cardioprotective effect of sodium tanshinone IIA sulfonate and the optimizing of therapeutic time window in myocardial ischemia/reperfusion injury in rats,” Atherosclerosis, vol. 235, no. 2, pp. 318–327, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. B. Wei, M.-G. You, J.-J. Ling et al., “Regulation of antioxidant system, lipids and fatty acid β-oxidation contributes to the cardioprotective effect of sodium tanshinone IIA sulphonate in isoproterenol-induced myocardial infarction in rats,” Atherosclerosis, vol. 230, no. 1, pp. 148–156, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. D. Sun, M. Shen, J. Li et al., “Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3β dependent pathway in experimental diabetic cardiomyopathy,” Cardiovascular Diabetology, vol. 10, article 4, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Hu, C. Zhai, G. Qian et al., “Protective effects of tanshinone IIA on myocardial ischemia reperfusion injury by reducing oxidative stress, HMGB1 expression, and inflammatory reaction,” Pharmaceutical Biology, vol. 53, no. 12, pp. 1752–1758, 2015. View at Publisher · View at Google Scholar
  62. M. Q. Zhang, Y. L. Zheng, H. Chen et al., “Sodium tanshinone IIA sulfonate protects rat myocardium against ischemia-reperfusion injury via activation of PI3K/Akt/FOXO3A/Bim pathway,” Acta Pharmacologica Sinica, vol. 34, no. 11, pp. 1386–1396, 2013. View at Publisher · View at Google Scholar
  63. Y.-S. Li, Z.-H. Wang, and J. Wang, “Effect of tanshinone II A on angiotensin receptor in hypertrophic myocardium of rats with pressure over-loading,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 28, no. 7, pp. 632–636, 2008. View at Google Scholar · View at Scopus
  64. Y.-S. Li, Z.-H. Wang, L. Yan et al., “Effect of tashinone on nitric oxide synthase in hypertrophic cardiomyocyte of rats suffered abdominal aorta constriction,” Zhongguo Zhong Yao Za Zhi, vol. 33, no. 12, pp. 1446–1450, 2008. View at Google Scholar · View at Scopus
  65. E.-Y. Tu, Y.-G. Zhou, Z.-H. Wang, Q.-S. Liang, and G.-T. Yang, “Effects of tanshinone II A on the myocardial hypertrophy signal transduction system protein kinase B in rats,” Chinese Journal of Integrative Medicine, vol. 15, no. 5, pp. 365–370, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. Li, Y. Yang, D. Yu, and Q. Liang, “The effect of tanshinone IIA upon the TGF-beta1/Smads signaling pathway in hypertrophic myocardium of hypertensive rats,” Journal of Huazhong University of Science and Technology [Medical Sciences], vol. 29, no. 4, pp. 476–480, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Fang, S.-W. Xu, P. Wang et al., “Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension,” Phytomedicine, vol. 18, no. 1, pp. 58–64, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Wang, X. Wu, Y. Bao et al., “Tanshinone IIA prevents cardiac remodeling through attenuating NAD (P)H oxidase-derived reactive oxygen species production in hypertensive rats,” Pharmazie, vol. 66, no. 7, pp. 517–524, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. H. Pang, B. Han, T. Yu, and Z. Peng, “The complex regulation of tanshinone IIA in rats with hypertension-induced left ventricular hypertrophy,” PLoS ONE, vol. 9, no. 3, Article ID e92216, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. F. Tang, X. Wu, T. Wang et al., “Tanshinone II A attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress,” Vascular Pharmacology, vol. 46, no. 6, pp. 427–438, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. Z.-Y. Fang, R. Lin, B.-X. Yuan, G.-D. Yang, Y. Liu, and H. Zhang, “Tanshinone IIA downregulates the CD40 expression and decreases MMP-2 activity on atherosclerosis induced by high fatty diet in rabbit,” Journal of Ethnopharmacology, vol. 115, no. 2, pp. 217–222, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Huang, M. Zheng, Y. Zhou et al., “Tanshinone IIA attenuates cardiac dysfunction in endotoxin-induced septic mice via inhibition of NADPH oxidase 2-related signaling pathway,” International Immunopharmacology, vol. 28, no. 1, pp. 444–449, 2015. View at Publisher · View at Google Scholar
  73. K.-J. Huang, H. Wang, W.-Z. Xie, and H.-S. Zhang, “Investigation of the effect of tanshinone IIA on nitric oxide production in human vascular endothelial cells by fluorescence imaging,” Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, vol. 68, no. 5, pp. 1180–1186, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. C.-C. Chang, C.-F. Chu, C.-N. Wang et al., “The anti-atherosclerotic effect of tanshinone IIA is associated with the inhibition of TNF-α-induced VCAM-1, ICAM-1 and CX3CL1 expression,” Phytomedicine, vol. 21, no. 3, pp. 207–216, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. X. Liu, C. Y. Guo, X. J. Ma et al., “Anti-inflammatory effects of tanshinone IIA on atherosclerostic vessels of ovariectomized ApoE−/− mice are mediated by estrogen receptor activation and through the ERK signaling pathway,” Cellular Physiology and Biochemistry, vol. 35, no. 5, pp. 1744–1755, 2015. View at Publisher · View at Google Scholar
  76. A. K. S. Wan, S. W. S. Leung, D.-Y. Zhu, and R. Y. K. Man, “Vascular effects of different lipophilic components of ‘Danshen’, a traditional Chinese medicine, in the isolated porcine coronary artery,” Journal of Natural Products, vol. 71, no. 11, pp. 1825–1828, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. B. I. Jugdutt, “Ischemia/Infarction,” Heart Failure Clinics, vol. 8, no. 1, pp. 43–51, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. P. Anversa, W. Cheng, Y. Liu, A. Leri, G. Redaelli, and J. Kajstura, “Apoptosis and myocardial infarction,” Basic Research in Cardiology, vol. 93, supplement 3, pp. 8–12, 1998. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Saraste, K. Pulkki, M. Kallajoki, K. Henriksen, M. Parvinen, and L.-M. Voipio-Pulkki, “Apoptosis in human acute myocardial infarction,” Circulation, vol. 95, no. 2, pp. 320–323, 1997. View at Publisher · View at Google Scholar · View at Scopus
  80. L. M. Buja, “Myocardial ischemia and reperfusion injury,” Cardiovascular Pathology, vol. 14, no. 4, pp. 170–175, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. E. Murphy and C. Steenbergen, “Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury,” Physiological Reviews, vol. 88, no. 2, pp. 581–609, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. A. P. Halestrap, S. J. Clarke, and S. A. Javadov, “Mitochondrial permeability transition pore opening during myocardial reperfusion—a target for cardioprotection,” Cardiovascular Research, vol. 61, no. 3, pp. 372–385, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. D. Garcia-Dorado, M. Ruiz-Meana, and H. M. Piper, “Lethal reperfusion injury in acute myocardial infarction: facts and unresolved issues,” Cardiovascular Research, vol. 83, no. 2, pp. 165–168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. D. M. Yellon and D. J. Hausenloy, “Myocardial reperfusion injury,” The New England Journal of Medicine, vol. 357, no. 11, pp. 1074–1135, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. Y.-I. Li, G. Elmer, and R. C. LeBoeuf, “Tanshinone IIA reduces macrophage death induced by hydrogen peroxide by upregulating glutathione peroxidase,” Life Sciences, vol. 83, no. 15-16, pp. 557–562, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Verma, P. W. M. Fedak, R. D. Weisel et al., “Fundamentals of reperfusion injury for the clinical cardiologist,” Circulation, vol. 105, no. 20, pp. 2332–2336, 2002. View at Publisher · View at Google Scholar · View at Scopus
  87. M.-Q. Zhang, J.-F. Tu, H. Chen et al., “Janus kinase/signal transducer and activator of transcription inhibitors enhance the protective effect mediated by tanshinone IIA from hypoxic/ischemic injury in cardiac myocytes,” Molecular Medicine Reports, vol. 11, no. 4, pp. 3115–3121, 2015. View at Publisher · View at Google Scholar · View at Scopus
  88. W.-J. Zhang, J. Feng, R. Zhou et al., “Tanshinone IIA protects the human blood-brain barrier model from leukocyte-associated hypoxia-reoxygenation injury,” European Journal of Pharmacology, vol. 648, no. 1–3, pp. 146–152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Yagi and S. Takeo, “Anti-inflammatory constituents, aloesin and aloemannan in Aloe species and effects of tanshinon VI in Salvia miltiorrhiza on heart,” Yakugaku Zasshi, vol. 123, no. 7, pp. 517–532, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. B. C. Bernardo, K. L. Weeks, L. Pretorius, and J. R. McMullen, “Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies,” Pharmacology & Therapeutics, vol. 128, no. 1, pp. 191–227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. S. P. Barry, S. M. Davidson, and P. A. Townsend, “Molecular regulation of cardiac hypertrophy,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 10, pp. 2023–2039, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Rohini, N. Agrawal, C. N. Koyani, and R. Singh, “Molecular targets and regulators of cardiac hypertrophy,” Pharmacological Research, vol. 61, no. 4, pp. 269–280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. P. M. Kang, P. Yue, Z. Liu, O. Tarnavski, N. Bodyak, and S. Izumo, “Alterations in apoptosis regulatory factors during hypertrophy and heart failure,” American Journal of Physiology & Heart and Circulatory Physiology, vol. 287, no. 1, pp. H72–H80, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. E. Teiger, V. D. Than, L. Richard et al., “Apoptosis in pressure overload-induced heart hypertrophy in the rat,” The Journal of Clinical Investigation, vol. 97, no. 12, pp. 2891–2897, 1996. View at Publisher · View at Google Scholar · View at Scopus
  95. V. P. M. van Empel and L. J. De Windt, “Myocyte hypertrophy and apoptosis: a balancing act,” Cardiovascular Research, vol. 63, no. 3, pp. 487–499, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Seddon, Y. H. Looi, and A. M. Shah, “Oxidative stress and redox signalling in cardiac hypertrophy and heart failure,” Heart, vol. 93, no. 8, pp. 903–907, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. F. Yang, P. Li, H. Li, Q. Shi, S. Li, and L. Zhao, “microRNA-29b mediates the antifibrotic effect of tanshinone IIA in postinfarct cardiac remodeling,” Journal of Cardiovascular Pharmacology, vol. 65, no. 5, pp. 456–464, 2015. View at Publisher · View at Google Scholar · View at Scopus
  98. R. Jeyaseelan, C. Poizat, H.-Y. Wu, and L. Kedes, “Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes,” The Journal of Biological Chemistry, vol. 272, no. 9, pp. 5828–5832, 1997. View at Publisher · View at Google Scholar · View at Scopus
  99. Y.-W. Zhang, J. Shi, Y.-J. Li, and L. Wei, “Cardiomyocyte death in doxorubicin-induced cardiotoxicity,” Archivum Immunologiae et Therapiae Experimentalis, vol. 57, no. 6, pp. 435–445, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. J. M. Berthiaume and K. B. Wallace, “Adriamycin-induced oxidative mitochondrial cardiotoxicity,” Cell Biology and Toxicology, vol. 23, no. 1, pp. 15–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. A. R. Lehenbauer Ludke, A. A.-R. S. Al-Shudiefat, S. Dhingra, D. S. Jassal, and P. K. Singal, “A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity,” Canadian Journal of Physiology and Pharmacology, vol. 87, no. 10, pp. 756–763, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. X.-H. Tian and J. H. Wu, “Tanshinone derivatives: a patent review (January 2006–September 2012),” Expert Opinion on Therapeutic Patents, vol. 23, no. 1, pp. 19–29, 2013. View at Publisher · View at Google Scholar · View at Scopus
  103. Y.-F. Bi, H.-W. Xu, X.-Q. Liu, X.-J. Zhang, Z.-J. Wang, and H.-M. Liu, “Synthesis and vasodilative activity of tanshinone IIA derivatives,” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 16, pp. 4892–4894, 2010. View at Publisher · View at Google Scholar · View at Scopus